10317 results for 'namepl inhibitor'

Introduction to TLR4 and Cancer Toll-like receptor 4 (TLR4) is a key component of the innate immune system, primarily responsible for detecting infections and initiating inflammatory resp

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d

Pancreatic cancer survival rates Despite recent advances in our understanding of this disease, pancreatic cancer is one of the world’s most lethal malignan

Introduction to CD80 and Its Role in Immune Activation CD80 is a critical immune checkpoint molecule that plays an essential role in T cell activation through co-stimulatory pathways. Exp

Introduction to TREM2 and Tumor-Associated Macrophages in CancerTREM2 (triggering receptor expressed on myeloid cells 2) is an immunoregulatory receptor primarily expressed on macrophages

Understanding the immune system's intricacies requires models that accurately reflect its complexity. The rat, as a model organism, plays a crucial role in immunological research, particularly in

Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a chronic, irreversible and ultimately fatal disease characterized by prog

Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including

Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab

Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re

Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli

Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest

B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role i

IntroductionThe human kinome is estimated to contain 518 genes, in comparison to the estimated 180 genes that comprise the phosphatome (Arena et al., 2005). These kinase genes represent a signif

Enhancing PD-L1 Stability: The Role of EZH2 InhibitionIn recent years, the role of PD-L1 (Programmed Death-Ligand 1) in cancer immunotherapy has garnered significant attention, particularly regarding

TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy and the treatment of autoimmune diseases. As a checkpoint receptor, TIGIT

Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha

Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons

Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to fight malignancies. Among the notable advancements in this field is the development of immune c